Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 10/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326849 | 0.87 | ACHE (0.43) | ACHESLC5A2CA12CA1CA9 | |
| SCHEMBL9014071 | 0.85 | CA12 (0.48) | SLC5A2CA12CA1CA9TYR | |
| SCHEMBL9014322 | 0.85 | CA12 (0.48) | SLC5A2CA12CA1CA9TYR | |
| SCHEMBL9014307 | 0.85 | CA12 (0.48) | SLC5A2CA12CA1CA9TYR | |
| SCHEMBL9013970 | 0.85 | CA12 (0.48) | SLC5A2CA12CA1CA9TYR | |
| SCHEMBL1076034 | 0.83 | TYR (0.49) | ACHESLC5A2TYR | |
| SCHEMBL5728675 | 0.83 | TYR (0.48) | SLC5A2TYR | |
| SCHEMBL4651595 | 0.83 | TYR (0.48) | SLC5A2TYR | |
| SCHEMBL868745 | 0.83 | TYR (0.48) | SLC5A2TYR | |
| SCHEMBL14975449 | 0.83 | TYR (0.48) | SLC5A2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050458-A1 | Compositions And Methods For Inducing Apopotosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ROBERTS SUZANNAH JANE (US) | 2024-02-15 | — | — | US | disclosed |
| US-20200360408-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | COGNATE 3 LLC | 2020-11-19 | — | — | US | disclosed |
| US-20200253998-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2020-08-13 | — | — | US | disclosed |
| US-20160113955-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160008388-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | BROWN JOE ERNEST (US) | 2016-01-14 | — | — | US | disclosed |
| US-20120251490-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110311478-A1 | Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium | BROWN JOE ERNEST (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311477-A1 | Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies | BROWN JOE ERNEST (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311476-A1 | Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation | BROWN JOE ERNEST (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2271350-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Cognate3, LLC. (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009145841-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | COGNATE 3, LLC (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090281047-A1 | Compositions And Methods For Immunotherapy | COGNATE3 LLC | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008388-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | ICOS, IL2, NFATC1 | ACHE 1809/4885SLC5A2 3415/4885CA12 451/4885 |
| US-20090281047-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | ACHE 1809/4885SLC5A2 3415/4885CA12 451/4885 |
| US-20240050458-A1 | Compositions And Methods For Inducing Apopotosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | ACHE 495/4885SLC5A2 1011/4885CA12 239/4885 |
| US-20110311478-A1 | Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium | NFATC1, MKI67, MYD88 | ACHE 3616/4885SLC5A2 3148/4885CA12 1844/4885 |
| US-20110311477-A1 | Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies | IDO1, MKI67, ADSL | ACHE 3767/4885SLC5A2 754/4885CA12 1607/4885 |
| US-20110311476-A1 | Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation | IDO1, TLR5, IDO2 | ACHE 3232/4885SLC5A2 1048/4885CA12 1801/4885 |
| US-20120251490-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | ACHE 1809/4885SLC5A2 3415/4885CA12 451/4885 |
| US-20200360408-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | ACHE 786/4885SLC5A2 1160/4885CA12 228/4885 |
| US-20200253998-A1 | Compositions And Methods For Immunotherapy | ICOS, NFATC1, IL2 | ACHE 1768/4885SLC5A2 3588/4885CA12 678/4885 |
| US-20160113955-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | ACHE 1809/4885SLC5A2 3415/4885CA12 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.